Hepatomegaly
Information
- Disease name
- Hepatomegaly
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03499808 | Active, not recruiting | Phase 2 | S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis | June 6, 2018 | July 31, 2025 |
| NCT00565097 | Completed | Phase 2/Phase 3 | Lanreotide as Treatment of Polycystic Livers | October 2007 | |
| NCT00426153 | Completed | Phase 2/Phase 3 | Octreotide in Severe Polycystic Liver Disease | January 2007 | October 2008 |
| NCT03801434 | Recruiting | Phase 2 | Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders | November 15, 2019 | November 30, 2025 |
| NCT02421354 | Terminated | Phase 2 | Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis | May 14, 2015 | April 13, 2018 |
| NCT03666117 | Unknown status | Prevalence of Hepatomegaly in Children and Adolescents With Type 1 Diabetes Mellitus | January 1, 2019 | January 1, 2020 | |
| NCT00771888 | Unknown status | Phase 2/Phase 3 | Open-Label Extension of LOCKCYST Trial | April 2008 | August 2009 |
| NCT02298634 | Withdrawn | Biomarker for Farber Disease (BioFarber) | August 20, 2018 | February 28, 2021 | |
| NCT02298699 | Withdrawn | Biomarker for Sly Disease (MPS VII) (BioSly) | August 20, 2018 | February 28, 2021 | |
| NCT01331642 | Withdrawn | Biomarker for Gaucher Disease: BioGaucher (BioGaucher) | August 20, 2018 | February 28, 2021 |
- HPO alt_id (Human Phenotype Ontology)
- HP:0001393
- HPO alt_id (Human Phenotype Ontology)
- HP:0001398
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0002240
- MeSH unique ID (MeSH (Medical Subject Headings))
- D006529